Lv4
490 积分 2022-10-16 加入
Antibiotic resistance of Helicobacter pylori in Mainland China: A focus on geographic differences through systematic review and meta-analysis
1个月前
已完结
Beyond Nine Months: Real-World Efficacy and Safety of Extended Nefecon Therapy in IgAN
1个月前
已关闭
Nefecon Treatment in Patients with IgAN: A Real-World Observational Study
1个月前
已关闭
Efficacy and Safety of Nefecon in Patients with IgA Nephropathy from Mainland China: 2-Year NefIgArd Trial Results
1个月前
已完结
Nefecon in IgA nephropathy: real-world renal efficacy, safety profile, and treatment response from a 9-month retrospective cohort analysis
1个月前
已完结
Evaluating vonoprazan bismuth‐containing triple therapy versus quadruple therapy for Helicobacter pylori
3个月前
已完结
Bismuth add-on improves the efficacy of 2-week tegoprazan-based triple therapy for first-line Helicobacter pylori eradication: a real-world evidence study
3个月前
已完结
Vonoprazan High-Dose Dual, Vonoprazan Triple, and Rabeprazole Reverse Hybrid Therapies for First-Line Treatment of Helicobacter pylori Infection: A Multicenter Randomized Trial
3个月前
已完结
Vonoprazan-based triple therapy for Helicobacter pylori resistant to first-line regimens: A guideline-compliant 14-day multicenter study in Egypt
3个月前
已完结
Comparative Efficacy and Safety of Potassium-Competitive Acid Blocker-Based Dual, Triple, and Quadruple Regimens for First-Line Helicobacter pylori Infection Treatment: A Systematic Review and Network Meta-Analysis
3个月前
已完结
皖公网安备34019202002308
